Crimean–Congo hemorrhagic fever virus, or CCHFV, belongs to the order Bunyavirales and is transmitted primarily by infected ticks, especially ticks of the genus Hyalomma. People can also become infected through contact with the blood or tissues of viremic animals, and human-to-human transmission can occur when bodily fluids from an infected person reach another individual. Clinical outcomes vary widely. Some infections cause mild or nonspecific illness, while severe disease can progress rapidly, with bleeding, circulatory collapse, liver dysfunction and multiorgan failure. The virus’s broad geographic distribution and ability to move between wildlife, livestock, ticks and people make it a persistent public-health concern.

The viral surface is dominated by a glycoprotein complex that helps CCHFV enter host cells and is exposed to the immune system. Like many enveloped viruses, CCHFV produces proteins that must perform several tasks at once: assemble into new viral particles, interact with host-cell membranes and evade or withstand immune attack. GP38 is produced from the virus’s glycoprotein precursor and is distinct from the better-known entry proteins that form the mature viral surface machinery. That distinction matters because immune responses directed against one part of a viral protein complex may not recognize another part, and because some viral proteins can be conserved across strains even when exposed regions change.

The paper by Wang, Monticelli, Berrigan and colleagues focuses on GP38 from the M18-China isolate and reports that this protein “confers broad immunological breadth.” In practical terms, the study’s title indicates that GP38 can generate or support immune recognition extending across a wide range of viral antigenic features or virus variants. The supplied publication information does not provide the study’s experimental sample sizes, animal models, antibody sequences, structural data or neutralization measurements, so those details cannot be used to quantify the effect. What can be concluded from the reported finding is that the investigators have identified an immune-relevant property in a protein that has received less attention than the virus’s principal entry glycoproteins.

That result is important because viral evolution can undermine highly narrow immune defenses. Antibodies often recognize three-dimensional shapes on the surface of proteins, known as epitopes. If mutations alter those shapes, an antibody may bind less effectively or fail to bind altogether. A target with broader conservation, or one that presents multiple shared epitopes, may offer a better foundation for countermeasures intended to work against genetically diverse viral lineages. Broad recognition does not automatically mean broad protection: an antibody can bind to a protein without blocking infection, and an immune response can be detectable without being strong enough to prevent disease. The crucial next question is therefore whether GP38-directed responses interfere with viral replication, reduce disease severity or improve survival in appropriate experimental systems.

The discovery also has potential significance for diagnostics. Many tests for viral disease detect either the virus’s genetic material or antibodies produced by an infected person. Molecular tests can be highly specific but may require specialized equipment and must be performed while viral RNA is still present at detectable levels. Serological tests, by contrast, can reveal prior exposure through antibodies against viral proteins, but their performance depends on the selected antigen. A protein that is recognized across diverse CCHFV isolates could help researchers develop assays less vulnerable to strain-specific differences. At the same time, broad binding can create a technical challenge: a diagnostic antigen must distinguish genuine CCHFV exposure from cross-reactive responses to related viruses. GP38’s value for testing will therefore depend on how specifically it is recognized and how consistently it performs in samples from people with confirmed infection.

For vaccine research, the appeal of GP38 lies in the possibility of adding a new component to an immune-targeting strategy. Most vaccine development against enveloped viruses emphasizes surface proteins involved directly in entry because antibodies that block those proteins can prevent infection at the earliest stage. Yet a successful vaccine may need to stimulate several layers of immunity, including antibodies against multiple viral proteins and T cells that identify infected cells. Incorporating an antigen such as GP38 could broaden the range of immune responses generated by vaccination, particularly if the protein contains conserved regions shared among viral lineages. Whether it can do so safely and effectively remains an open question. Researchers would need to establish the protein’s structure, its accessibility during natural infection, the quality of the antibodies it induces and its performance when combined with other CCHFV antigens.

The study may also encourage a closer look at how CCHFV’s accessory and structural proteins interact with the immune system. Viral proteins that are not the dominant entry factors are sometimes overlooked because they do not present an obvious target for neutralizing antibodies. However, they may still contain conserved molecular surfaces, influence how viral particles are assembled or shape the immune response in ways that affect disease. Understanding GP38 could therefore contribute to a more complete map of the virus rather than simply producing a single candidate antigen. Such basic knowledge is valuable for a pathogen whose biology remains less thoroughly characterized than that of viruses such as influenza, HIV or SARS-CoV-2.

Important hurdles remain before the reported property can translate into a medical countermeasure. CCHFV research requires high-containment facilities because the virus can cause severe human disease and can spread through contact with infectious material. That limits the number of laboratories able to perform live-virus experiments and slows the progression from molecular observation to preclinical validation. Researchers must also account for the virus’s genetic diversity, differences in immune responses among individuals and the difficulty of conducting clinical trials for a sporadic disease that appears in geographically scattered outbreaks. The M18-China isolate provides a valuable reference point, but a broadly useful intervention would need to be tested against additional isolates and evaluated in systems that reflect the complexity of human infection.

For now, the central message is one of opportunity rather than immediate clinical impact. GP38 from the M18-China isolate has been reported as a protein with broad immunological relevance, expanding the list of CCHFV components that may be useful for understanding immunity and designing countermeasures. The finding could help shift attention toward a more inclusive view of viral antigens, in which less prominent proteins complement the major entry machinery. Further work will determine whether GP38-directed immunity merely recognizes the virus or can actually control it. If subsequent studies demonstrate cross-strain protection, reliable diagnostic performance or therapeutic antibody activity, this small viral protein could become an important piece of the global effort to prepare for Crimean–Congo hemorrhagic fever.

CCHFV belongs to the family Nairoviridae and carries its genetic information as a segmented, negative-sense RNA genome. The virus is primarily associated with Hyalomma ticks, which can acquire it while feeding on infected animals and later transmit it to other hosts. Humans may become infected through tick bites or contact with the blood and tissues of infected animals, including during slaughtering, veterinary procedures, or animal handling. Although many infections are mild or clinically unapparent, severe disease can develop rapidly, producing fever, vascular injury, bleeding, organ dysfunction, and, in some cases, death. This broad clinical spectrum makes early laboratory confirmation essential, yet it also complicates recognition in the field.

The sheep model examined by Gutjahr, Michaely, Bost and their collaborators addresses a central question in viral pathogenesis: where does CCHFV go after entering the body, and how does the timing of viral presence in different tissues affect the ability to detect it? Viral dissemination is not simply a matter of measuring whether an animal is infected. It involves tracking the movement of virus or viral genetic material through blood, organs, and potentially tissues that may be relevant to transmission or diagnosis. Such mapping can reveal which biological compartments become infected first, how long the virus remains detectable, and whether different samples provide different windows for reliable testing.

For diagnostic science, these details are crucial. Molecular assays such as reverse-transcription polymerase chain reaction detect viral RNA, usually by converting the RNA into complementary DNA and amplifying selected genomic sequences. The method can be highly sensitive, but its performance depends on the quality and timing of the sample. Viral RNA may be abundant in blood during one phase of infection and more readily detected in organs or other tissues at another. A negative result from one specimen therefore does not always exclude infection, particularly when sampling occurs early, late, or after viral levels have changed. By examining infection in sheep under controlled conditions, the study can help define which specimens are most informative and when they should be collected.

The work also speaks to the difference between detecting a virus and understanding its biological activity. Viral RNA can persist after infectious virus has declined, while infectious particles may be present at levels that are difficult to measure directly. Conversely, a low concentration of RNA in blood may still indicate an active infection or a risk of transmission through contaminated material. Experimental infection studies can compare molecular detection with tissue distribution and pathological observations, helping researchers interpret test results in the context of disease progression. That distinction is particularly important for CCHFV, where laboratory safety requirements are stringent and opportunities to study naturally infected animals are limited.

Sheep are a valuable model in this area because they are relevant to the ecology of CCHFV and may encounter infected ticks in regions where the virus circulates. Livestock can become infected without displaying obvious signs, yet they may develop transient viraemia—the presence of virus in the bloodstream—that enables ticks to acquire the pathogen during feeding. Understanding this period is important not only for animal health but also for estimating the risk posed to farmers, veterinarians, slaughterhouse workers, and others who handle animals or animal products. A controlled sheep study can isolate variables that are difficult to separate during field investigations, including the timing of infection, the amount of virus administered, and the relationship between clinical signs and laboratory findings.

The diagnostic implications extend beyond animal surveillance. Human CCHFV cases are often identified using a combination of clinical history, exposure information, molecular testing, and, later in the infection, serology. Antibody-based tests detect the host immune response rather than the virus itself and may become informative only after antibodies have developed. Molecular testing is therefore particularly important during the acute phase, when rapid decisions about patient isolation, contact tracing, and clinical management are required. Insights from animal tissue distribution may support more rational sampling strategies and help laboratories understand why test sensitivity can vary over the course of infection. They may also aid the evaluation of new assays designed to detect conserved regions of the viral genome.

The study has significance for a One Health approach, which treats human, animal, and environmental health as connected rather than separate domains. CCHFV transmission is shaped by climate, tick abundance, livestock movement, land use, occupational exposure, and access to diagnostic services. As tick habitats expand or shift, surveillance systems may need to monitor both animals and people across wider geographical areas. Research that clarifies how infection unfolds in a relevant livestock host can contribute to preparedness by improving protocols for sample collection, biosafety, veterinary monitoring, and outbreak investigation. It may also provide a framework for comparing viral strains or host responses in future experiments, although such comparisons require careful attention to differences in virus, host, and experimental design.

The findings presented in npj Viruses are therefore positioned at the intersection of pathogenesis and public-health readiness. By focusing on viral dissemination in experimentally infected sheep, Gutjahr and colleagues address the biological processes that determine what can be detected, where it can be detected, and when testing is most likely to succeed. The research does not eliminate the challenges posed by CCHFV’s high-consequence nature, but it strengthens the evidence base needed to confront them. Better knowledge of tissue distribution and diagnostic timing can support earlier recognition of infection, more effective surveillance of livestock and exposed workers, and a clearer understanding of how a tick-borne virus moves between animals and humans.

Subject of Research: Viral dissemination and diagnostic insights from experimental infection of sheep with Crimean-Congo hemorrhagic fever virus

Article Title: Viral dissemination and diagnostic insights from experimental infection of sheep with Crimean-Congo hemorrhagic fever virus

Article References: Gutjahr, B., Michaely, L.M., Bost, C. et al. Viral dissemination and diagnostic insights from experimental infection of sheep with Crimean-Congo hemorrhagic fever virus. npj Viruses 4, 39 (2026). https://doi.org/10.1038/s44298-026-00228-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s44298-026-00228-y

Keywords: Crimean-Congo hemorrhagic fever virus, CCHFV, viral dissemination, sheep, experimental infection, diagnostic testing, zoonotic disease, tick-borne virus, One Health, veterinary virology

Published in npj Viruses, the study examines the viruses in mice lacking the type I interferon receptor, known as IFNAR−/− mice. Type I interferons, including interferon-alpha and interferon-beta, are among the body’s earliest antiviral defenses. They activate hundreds of genes that restrict viral replication and help coordinate innate and adaptive immunity. By removing the receptor required for cells to respond to these signals, researchers create an animal model that is highly vulnerable to CCHFV infection and can support the development of severe disease.

The use of IFNAR−/− mice is particularly important for studying CCHFV because ordinary laboratory mice often resist infection or develop disease that does not reproduce the rapid progression seen in humans. The model does not replicate every feature of human Crimean-Congo hemorrhagic fever, but it allows researchers to compare viral isolates under controlled conditions. A side-by-side design also reduces the risk that differences in housing, timing, animal age or experimental handling will be mistaken for genuine differences between viruses.

Rohde and colleagues evaluated the two isolates using a combination of clinical and virological measurements. Such assessments typically include changes in body weight, temperature or activity, the onset and progression of disease signs, survival, viral RNA levels in blood and organs, and microscopic evidence of tissue injury. Together, these measurements distinguish between viruses that replicate efficiently, viruses that spread to particular organs, and viruses that cause severe disease even when their overall quantities are similar.

The comparison demonstrates why the isolate used in an animal experiment can be a decisive variable. Closely related CCHFV isolates may differ in the speed at which they establish infection, the extent to which they disseminate through the body and the severity of the resulting pathology. Differences can arise from mutations affecting viral replication, interactions with host proteins, the ability to counter innate immune responses or the balance between viral growth and inflammatory injury. These effects may not be apparent when experiments are conducted with only one strain.

CCHFV is an enveloped, negative-sense RNA virus in the family Nairoviridae. Its genome is divided into three segments that encode structural and non-structural proteins, including the nucleoprotein, the surface glycoprotein precursor and an RNA-dependent RNA polymerase. The segmented genome creates opportunities for genetic reassortment when different viruses infect the same cell, while the error-prone nature of RNA replication generates additional diversity. This biological flexibility helps explain why isolates collected in different regions or hosts can show distinct phenotypes in laboratory systems.

The study’s findings have consequences beyond the immediate comparison. Animal models are widely used to evaluate vaccines, antibody treatments, antiviral compounds and supportive-care strategies. If two isolates produce different disease trajectories in the same mouse background, a treatment that appears effective against one virus may not perform identically against another. Conversely, a model based on an especially aggressive isolate could make an intervention appear less effective than it would be against a broader range of circulating viruses. Careful strain selection and transparent reporting are therefore essential for reproducible CCHFV research.

The work also highlights the limitations of relying on a single laboratory model. IFNAR−/− mice lack a central component of antiviral immunity, and their response to infection cannot be directly equated with the response of people, whose disease is influenced by age, genetics, prior immune activation, coagulation pathways and other factors. The model is nevertheless valuable because it provides a consistent framework for comparing viruses and identifying mechanisms that can later be tested in more complex systems, including immune-competent animals, organoid cultures and human clinical samples.

For public-health researchers, the study reinforces the importance of treating CCHFV as a genetically diverse threat rather than as one standardized pathogen. The virus is maintained in nature through cycles involving ticks and animal hosts, and human infections occur across a broad geographic range. Surveillance programs that sequence viruses and link genetic data with clinical information may help determine whether particular viral lineages are associated with altered transmissibility or disease severity. The side-by-side approach used in this study offers a practical foundation for connecting viral genotype with biological behavior.

By placing two isolates under identical experimental conditions, the researchers provide a clearer framework for interpreting virulence studies and for designing future countermeasure trials. The broader message is that model systems are only as informative as the viral strains selected for them. As CCHFV research expands, comparisons across multiple isolates, host backgrounds and immune conditions will be critical for identifying results that are truly generalizable. The study therefore contributes not only to understanding these two viruses, but also to a more rigorous strategy for investigating one of the world’s most serious tick-borne viral diseases.

Subject of Research: Comparative pathogenicity and disease biology of two Crimean-Congo hemorrhagic fever virus isolates in IFNAR−/− mice.

Article Title: Side-by-side evaluation of two Crimean-Congo hemorrhagic fever virus isolates in IFNAR−/− mice.

Article References: Rohde, C., Werner, AD., Gellhorn Serra, M. et al. Side-by-side evaluation of two Crimean-Congo hemorrhagic fever virus isolates in IFNAR^−/− mice. npj Viruses 4, 35 (2026). https://doi.org/10.1038/s44298-026-00216-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s44298-026-00216-2

Keywords: Crimean-Congo hemorrhagic fever virus, CCHFV, IFNAR−/− mice, viral isolates, viral pathogenesis, animal models, interferon signaling, hemorrhagic fever, antiviral research.

In new work published in Nature, researchers focused on the CCHFV Large (L) protein, which serves as the polymerase responsible for copying the viral genome. The L protein is among the largest polymerases in the Bunyavirales order, making it both biologically intriguing and technically challenging to study. By reconstituting RNA synthesis in vitro and capturing elongating L–RNA complexes, the team gained a direct view of how the polymerase is arranged during active replication.

The study defines the essential cofactors required for CCHFV-L RNA synthesis outside the cell. Using these conditions, the authors isolated structures associated with RNA elongation and determined their conformations. This approach allowed them to move from inference to detailed structural visualization of a replication stage that is critical for antiviral target validation.

A striking finding is that CCHFV-L adopts a markedly enlarged architecture during RNA synthesis. Rather than being a static molecular machine, the polymerase appears to reorganize itself as it transitions into elongation-competent states. The enlarging architecture correlates with ordering of peripheral domains, suggesting that the polymerase’s “outer” regions become coordinated to support processive RNA copying.

These observations help explain how the large L protein accommodates RNA and catalysis within a dynamic assembly. They also clarify how peripheral domain positioning may regulate key steps such as nucleotide selection, translocation, and chain extension. For drug discovery, such mechanistic detail is valuable because it links inhibitor effects to specific conformational states of the polymerase.

The authors also mapped inhibition mechanisms of two CCHFV-L targeting compounds. One is WXSH0208, a baloxavir-derived experimental drug reported to act against the polymerase. Structural analyses and biochemical behavior indicate that WXSH0208 inhibits CCHFV-L through endonuclease interference, disrupting a catalytic function required during RNA synthesis.

In parallel, the nucleoside analogue 2′-deoxy-2′-fluorocytidine provides another orthogonal inhibition mode. The compound shows nanomolar cellular potency and, in this work, blocks RNA synthesis via post-translocation chain termination. Structurally supported, this suggests the analogue is incorporated and then prevents further elongation after the polymerase advances.

Together, the structures provide a platform for rational optimization of inhibitors aimed at CCHFV-L. By showing how both endonuclease inhibition and chain termination correspond to distinct polymerase conformations, the study offers guidance for designing molecules that are better tailored to the viral replication machinery.

This research therefore advances Viral science news by transforming CCHFV-L from a biochemical target into a mechanistically described, drug-interpretable system. With CCHFV continuing to demand new countermeasures, such structural frameworks may accelerate the path toward effective therapies against a virus with limited treatment options.

Subject of Research: Crimean–Congo haemorrhagic fever virus (CCHFV) polymerase (CCHFV-L)

Article Title: Structures and inhibition of the Crimean–Congo haemorrhagic fever virus polymerase

Article References: Xue, L., Gui, J., Pan, H. et al. Structures and inhibition of the Crimean–Congo haemorrhagic fever virus polymerase. Nature (2026). https://doi.org/10.1038/s41586-026-10701-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10701-6

Keywords: CCHFV-L, RNA-dependent RNA polymerase, WXSH0208, 2′-deoxy-2′-fluorocytidine, endonuclease inhibition, chain termination, Bunyavirales, antiviral inhibitors

Using high-resolution cryo-EM, the team solved structures covering the polymerase elongation cycle. A key accomplishment is a polymerase elongation complex at 3.0 Å resolution, capturing CCHFV L engaged with RNA and substrate in an informative intermediate state. This provides mechanistic insight into how the enzyme performs both early and later stages of RNA elongation.

The structures reveal that CCHFV L contains pronounced additions and insertions across three major functional regions: an endonuclease module, an RNA-dependent RNA polymerase (RdRP) center, and a cap-binding domain. Rather than behaving like a simple scaffold, these expanded segments remodel the geometry of RNA engagement.

Notably, the additional elements extend RNA binding paths on both sides of the RdRP active site. This reshaping likely helps stabilize the nascent RNA and coordinate product movement through the polymerase channel. Together, the interfaces form interaction networks that are consistent with experimental evidence from CCHFV minigenome assays.

To translate structure into therapy, the study evaluates nucleotide analog inhibitors (NAs) carrying ribose 2′-modifications identical to those found in the hepatitis C drug sofosbuvir. The analogs specifically and efficiently inhibit CCHFV RdRP, acting through an immediate chain termination mechanism during RNA synthesis.

Structural and biochemical observations align with the idea that the analogs are incorporated into the growing RNA chain, after which elongation halts rapidly. This “stop” effect contrasts with delayed termination pathways sometimes observed for other substrate mimics.

To further validate mechanism and potency, the researchers employ sofosbuvir–hepatitis C virus RdRP as a reference and perform competition assays in the presence of corresponding natural nucleotides (NTPs). These experiments demonstrate how competing substrates influence inhibitor performance, supporting the NA-specific engagement of the CCHFV RdRP active site.

Overall, the work delivers both a detailed blueprint of CCHFV L RNA synthesis and a compelling antiviral strategy. By pinpointing structural determinants and showing rapid chain termination by clinically known analog chemistry, the study advances Viral Science News coverage toward actionable inhibitor development against this high-consequence pathogen.

Subject of Research: CCHFV polymerase structure and nucleotide analog inhibition

Article Title: RNA synthesis and substrate analog inhibition in the CCHFV polymerase

Article References: Jia, H., Tang, B., Liu, S. et al. RNA synthesis and substrate analog inhibition in the CCHFV polymerase. Nature (2026). https://doi.org/10.1038/s41586-026-10913-w

Image Credits: AI Generated

DOI: 10.1038/s41586-026-10913-w

Keywords: Crimean-Congo hemorrhagic fever virus, Nairoviridae, L polymerase, RdRP, elongation complex, cryo-EM, nucleotide analog, sofosbuvir, chain termination, minigenome assay

Orthonairoviruses include Crimean-Congo hemorrhagic fever virus, notorious for causing severe hemorrhagic illness in humans. The study centers on ovarian tumor domain proteases (OTUs), viral enzymes that undermine host immune signaling rather than simply evading detection at the surface.

Under normal conditions, immune pathways rely on small regulatory proteins such as ubiquitin and ISG15 to coordinate detection and antiviral responses inside infected cells. The research shows that OTUs can remove these signals, effectively silencing cellular communication routes that would otherwise flag infection and amplify defense.

The investigators report that the virus employs OTUs at multiple stages to “disarm” immunity, increasing the likelihood that infection takes hold. Beyond this known immune-suppressing activity, the team also describes a third, previously uncharacterized function of OTUs. While its role in immune evasion appears meaningful, the underlying mechanism remains to be fully defined.

The paper is published in ACS Infectious Diseases and selected as an ACS Editors’ Choice. It examines how OTUs disrupt critical intracellular processes, providing a structural and functional view of the virulence factors used by emerging human nairoviruses.

Importantly, the findings extend beyond theory. Orthonaïroviruses continue to be discovered worldwide, and in the United States the Pacific Coast tick already transmits several serious bacterial and viral diseases. Prior work has identified nairoviruses associated with these ticks, raising the possibility of unrecognized exposure pathways for humans.

The authors emphasize that the OTU mechanism studied is highly compatible with humans, suggesting that at least some tick-borne orthonairoviruses may interact efficiently with human immune machinery. Combined with existing tick-to-human transmission of other diseases, this compatibility increases the likelihood of contact that could go undetected without targeted surveillance.

Although the results strengthen concerns about pandemic potential within the broader Nairoviridae family, the researchers caution that more work is needed to determine whether the virus currently infects people and causes disease. Future studies are expected to evaluate human exposure across the tick’s geographic range.

Until then, the team advises continued prevention of tick bites and attention to the specific tick species involved, since different species may carry different, sometimes unmonitored pathogens. The study also reinforces the need for rapid identification tools and sustained monitoring to improve readiness for future outbreaks driven by evolving viruses.

Subject of Research: Not applicable
Article Title: Insights into the Structure and Function of the OTU Protease Virulence Factors from Emerging Human Nairoviruses
News Publication Date: 13-Jul-2026
Web References: https://pubs.acs.org/doi/full/10.1021/acsinfecdis.6c00320 ; http://dx.doi.org/10.1021/acsinfecdis.6c00320
References: ACS Infectious Diseases (DOI: 10.1021/acsinfecdis.6c00320)
Image Credits:

Keywords: orthonairoviruses; tick-borne viruses; OTU protease; immune evasion; ubiquitin; ISG15; ubiquitination; ISG15 signaling; nairovirus; Nairoviridae; pandemic potential

In this study, Scott Pegan, along with his colleagues, explores how nairoviruses circumvent the host’s innate defenses. A notable example of this family is the Crimean-Congo hemorrhagic fever virus (CCHFV), a pathogen with a high fatality rate posing a global threat, particularly to civilians and military personnel in endemic areas across Africa, the Middle East, and Asia. Understanding the immune evasion strategies of such viruses is critical for developing effective countermeasures and improving biosurveillance capabilities.

Nairoviruses produce a specialized enzyme—an ovarian tumor domain-containing protease—that selectively cleaves ubiquitin and ISG15 molecules attached to human proteins. Ubiquitin and ISG15 modifications typically function as alarm signals to the immune system, marking infected cells for destruction. By removing these small protein tags, nairoviruses render themselves invisible to host defenses, enabling uninterrupted replication and pathogenesis.

The investigators analyzed enzymatic activity from four different nairovirus species: three recently identified orthonairoviruses isolated from patients in Asia and an additional virus known as Pacific Coast tick nairovirus (PCTNV) found in ticks but not yet confirmed in human infections. Their assays revealed that the PCTNV enzyme exhibited the highest efficiency in cleaving ubiquitin and ISG15 from human proteins, suggesting a superior ability to suppress immune detection compared to its counterparts.

Given that PCTNV is transmitted by a tick species known to bite humans and capable of carrying other diseases such as Rocky Mountain spotted fever, these findings raise concerns about potential human exposure risks, especially along the U.S. West Coast. This highlights the urgent need for vigilance, not only regarding tick bites themselves but also concerning the species of ticks involved, as they may harbor previously unrecognized pathogens.

Expanding on this work, Pegan’s team collated ubiquitin cleavage data from 13 nairovirus species to train computational models aimed at distinguishing pathogenic viruses from less harmful ones. This represents a promising avenue toward automated biosurveillance systems capable of real-time detection and risk assessment of emerging tick-borne viruses.

Overall, this study emphasizes the complex interplay between nairoviruses and human immune defenses and underscores the importance of integrated molecular and computational approaches to tackle the growing threat of these stealthy viral pathogens.

Subject of Research: Immune evasion mechanisms of nairoviruses, a class of tick-borne viruses
Article Title: How an emerging class of tick-borne viruses escape human immune defenses
News Publication Date: 13-Jul-2026
Web References: http://dx.doi.org/10.1021/acsinfecdis.6c00320

Keywords

Viruses, Nairoviruses, Tick-borne pathogens, Immune evasion, Ubiquitin, ISG15, Protease, Biosurveillance

Crimean-Congo Hemorrhagic Fever Virus is a tick-borne pathogen that belongs to the Nairovirus genus within the Bunyaviridae family. It has a notorious reputation for causing severe hemorrhagic disease in humans, characterized by high fever, muscle pain, and in many cases, fatal hemorrhagic complications. The virus is primarily maintained in nature through a complex transmission cycle involving hard-bodied ticks, mainly of the genus Hyalomma, and various vertebrate hosts. Humans typically acquire the infection through tick bites or contact with blood or tissues of infected animals, making surveillance in livestock and wildlife critical for public health.

The serological survey employed in this study utilized enzyme-linked immunosorbent assays (ELISA) to detect immunoglobulin G (IgG) antibodies specific to CCHFV in serum samples collected from cattle and several wildlife species. The detection of these antibodies is a reliable marker of past infection and exposure, rather than active viral replication. Notably, the research team mapped the seroprevalence by municipality using Voronoï polygons to maintain confidentiality of farming locations and to address uneven sampling distribution. The color gradients, ranging from pale pink to dark red, visually represent the intensity of seroprevalence, with white areas indicating municipalities where samples were collected but tested seronegative.

The discovery of CCHFV antibodies in cattle is particularly alarming given the species’ role as amplifying hosts within the viral transmission cycle. Though cattle usually do not show symptoms, their infection enables the virus to propagate through tick populations that feed on them. Wildlife species testing positive for the antibodies suggest a broader ecological reservoir, underscoring the complexity of viral maintenance and potential spillover events. The interaction between wildlife, domestic animals, and tick vectors creates a dynamic epidemiological landscape that can facilitate virus emergence and spread into regions previously considered to be of low risk.

This study’s geographical focus on southern continental France provides valuable insight into the expanding range of CCHFV within Europe. Historically, the virus has been endemic in parts of Eastern Europe, the Middle East, Africa, and Asia, but its detection in French cattle and wildlife signals a westward expansion likely facilitated by climate change, animal migration, and human activities that alter habitats. The increased presence of Hyalomma ticks, which thrive in warmer climates, correlates with rising temperatures and milder winters in the region, thereby extending the seasonal transmission window for CCHFV.

Advanced molecular epidemiology and spatial analysis techniques were integral to the investigation, enabling the researchers to identify hotspots of viral exposure and potential ecological drivers. Factors such as land use patterns, livestock density, and wildlife population dynamics were considered to explain regional variability in seroprevalence. These explanatory factors support the hypothesis that environmental and anthropogenic changes are critical determinants in the emergence and maintenance of tick-borne diseases like CCHFV in temperate zones.

Importantly, the study underscores the necessity of an integrated One Health approach to monitor, predict, and mitigate the risks posed by CCHFV. Given the zoonotic nature of the virus, collaboration between veterinary health professionals, ecologists, public health authorities, and epidemiologists is essential to develop effective surveillance and control strategies. Enhanced awareness among farmers, veterinarians, and the general public about tick control measures and protective behaviors can also reduce human exposure to infected vectors and animal hosts.

While the seroprevalence in this study was reported to be above 2%, which might appear modest, it is significant in the context of a virus with potentially fatal consequences and the absence of prior documented circulation in this particular geographical area. The silent circulation of antibodies in cattle and wildlife implies the risk of sudden human cases, which can escalate into localized outbreaks if unrecognized and unmanaged. Early detection and reporting mechanisms are thus critical components of regional healthcare preparedness.

The research team acknowledged that the detection of antibodies does not equate to active infection in the sampled animals, but rather reflects prior exposure and immune response. Consequently, further virological studies, including virus isolation and tick vector surveillance, are necessary to confirm active transmission cycles and identify the precise mechanisms driving viral persistence. Such studies could inform targeted interventions aimed at interrupting virus propagation among animal reservoirs and vectors.

Funding from notable agencies including the French Ministry of Agriculture’s General Directorate for Food, European Funds for Regional Development, and the French Establishment for Fighting Zoonoses facilitated this study. The collaboration emphasizes the importance of investing in zoonotic disease research within non-endemic countries to prepare for emerging infectious threats. Given the ecological complexity and public health implications, continued support for multidisciplinary investigations is paramount for safeguarding both animal and human populations.

This unprecedented detection of Crimean-Congo Hemorrhagic Fever antibodies in France sets a precedent that encourages countries within Europe and beyond to reassess their own tick-borne disease surveillance frameworks. The evolving epidemiology of CCHFV highlights a larger global health challenge posed by vector-borne viruses, demanding innovative research, heightened vigilance, and comprehensive control measures in the face of environmental variability and globalization.

In conclusion, the identification of CCHFV presence in southern continental France marks a critical juncture in the epidemiological understanding of this formidable virus. This evidence of active circulation in cattle and wildlife demands immediate attention from scientific, veterinary, and public health communities. Through interdisciplinary collaboration, robust surveillance, and proactive public health policies, the risk of human infection and outbreak escalation can be curtailed, thus preserving both animal health and human lives against this insidious viral threat.

Subject of Research: Crimean-Congo Hemorrhagic Fever Virus seroprevalence in cattle and wildlife in southern continental France.

Article Title: First detection of Crimean Congo Hemorrhagic Fever antibodies in cattle and wildlife of southern continental France: Investigation of explanatory factors.

News Publication Date: 24-Sep-2025.

Web References: http://dx.doi.org/10.1371/journal.pone.0331875

Image Credits: Bernard et al., 2025, PLOS One, CC-BY 4.0.

Keywords: Crimean-Congo Hemorrhagic Fever Virus, CCHFV, tick-borne disease, seroprevalence, cattle, wildlife, Europe, France, zoonosis, Hyalomma ticks, emerging infectious diseases, One Health.

GP38 has garnered attention among researchers as it possesses unique properties that make it a potent candidate for vaccine development. Historically viewed as a significant target for medical interventions, the virus’s glycoprotein has presented a conundrum: while it is known to be crucial during the viral life cycle, a comprehensive understanding of its specific mechanisms has been lacking. This gap in knowledge has retarded the progress toward viable CCHFV vaccines and treatments, making the newly published research even more critical.

A pivotal study published in Science Translational Medicine reveals how GP38 functions independently of its role in the biogenesis of viral glycoproteins. Researchers meticulously examined how this glycoprotein interacts with host cells and elucidates the mechanisms by which it can act as a "viral toxin." This finding not only provides insight into GP38’s role in viral pathogenesis but also underscores its potential as a focal point for the rational design of therapeutics targeting CCHFV.

The research emphasizes that GP38 prompts endothelial hyperpermeability, an essential feature in the virus’s ability to cause disease. Endothelial cells line blood vessels, and their integrity is vital for maintaining vascular homeostasis. Perturbations in their function, such as those induced by GP38, can lead to significant vascular leakage. Thus, understanding how GP38 operates provides new avenues for targeting these pathological mechanisms in treatments and vaccine designs.

Andrew Herbert, a senior author of the study, stresses that GP38 is not merely a viral structural component; rather, it triggers critical changes in the host’s vascular functionality. By promoting leakage from blood vessels, GP38 facilitates the virus’s spread and increases its pathogenicity. This revelation marks a paradigm shift in how scientists view viral glycoproteins, highlighting the need to reconsider their roles beyond initial assumptions related strictly to viral entry and replication.

Critical results from this study indicate that GP38-specific antibodies can help mitigate the adverse vascular effects induced by the glycoprotein. The research indicates that these antibodies are particularly effective in limiting vascular leak and managing the dissemination of the virus throughout the body. Such findings lend credence to the potential for developing immunotherapeutics that specifically target GP38, which could significantly enhance patient outcomes in CCHFV infections.

Experimental models using CCHFV-challenged mice further corroborate these findings. The introduction of exogenous GP38 into these models exacerbated previously established vascular leak, reinforcing the notion that GP38 itself acts as a virulent factor. Hence, additional research focusing on how to generate neutralizing or protective antibodies against GP38 could yield significant benefits, offering a viable path toward clinical applications that may alter the trajectory of CCHFV infections.

Past studies, while illuminating certain aspects of GP38’s function, have not provided definitive answers regarding the mechanisms through which GP38-specific monoclonal antibodies exert their protective effects. This most recent publication serves to bridge that knowledge gap. By identifying the precise interactions and pathways involved in GP38-mediated vascular leakage, researchers are equipped with the insights necessary to exploit GP38’s vulnerabilities as targets for therapeutic intervention.

The collaboration between scientists from the U.S. Army Medical Research Institute of Infectious Diseases, Albert Einstein College of Medicine, and the University of California, Berkeley, underscores the multifaceted approach needed to address CCHFV. By uniting resources and expertise from various scientific disciplines, this research has been able to navigate the complexity of viral-host interactions and offer a sophisticated understanding of CCHFV pathology.

Understanding GP38’s dual role as both a viral glycoprotein and a pathogenic factor opens up discussions regarding vaccine strategies. Since no licensed vaccines currently exist for CCHFV, incorporating GP38 as a vaccine target could potentially enhance the immune response against the virus, allowing for greater protection against both infection and severe disease outcomes. Future investigational studies will likely delve deeper into the immune responses elicited by GP38-targeting strategies, possibly laying the groundwork for vaccine trials that leverage these novel insights.

Moreover, the ongoing research highlights the critical need for federal funding aimed at infectious diseases such as CCHFV, especially given its classification as a priority pathogen by global health organizations. The medical community must be equipped with the knowledge and resources to tackle emerging viral threats. Only through sustained investment can we hope to develop robust defenses against such pathogens that pose significant risks to public health.

The promising data emerging from these recent studies could provide a transformative impact not just on CCHFV research but on the broader landscape of viral pathogenicity. Exploring GP38’s contributions to viral spread and its role in eliciting vascular leakage holds the potential to unlock not only new therapeutic avenues for CCHFV but also insights that could apply to other viral infections characterized by similar pathophysiological processes. This unique intersection of virology and immunology demonstrates the intricacies involved in developing effective strategies that could redefine our approach to managing viral diseases in the future.

Given the historical context of how quickly infectious diseases can escalate into global threats, the urgency for advancing research in CCHFV and its glycoproteins cannot be overstated. The modern challenges presented by infectious diseases require a proactive and strategically informed response, and the recent breakthroughs concerning GP38 and its role in pathogenesis offer a beacon of hope in this endeavor. As such, continuing to pursue research avenues focusing on GP38 could yield substantial benefits in our pursuit of countermeasures against CCHFV, with implications that may echo across various diseases long into the future.

Subject of Research: Animals
Article Title: Antibodies targeting Crimean-Congo hemorrhagic fever virus GP38 limit vascular leak and viral spread
News Publication Date: 19-Feb-2025
Web References: DOI Link
References: None available
Image Credits: Credit: Felix Pahmeier, University of California, Berkeley

Keywords: Neutralizing antibodies, Viral infections, Viruses, Monoclonal antibodies, Glycoproteins, Ticks, Vascular cells, Endothelial cells, Fever, Protein functions, Binding proteins, Pathology